
(© MarekPhotoDesign.com - stock.adobe.com)
In A Nutshell
- A review of 69 clinical trials and more than 153,000 people found that calcium, vitamin D, or both together offer little to no protection against broken bones or falls in generally healthy older adults.
- Vitamin D alone showed zero benefit across more than 92,000 participants, with high confidence in that finding.
- Even when combined calcium and vitamin D produced technically significant results, the actual reductions in fracture risk were too small to matter clinically.
- People on prescription osteoporosis medications are a different story: current guidelines still recommend these supplements alongside those drugs.
For decades, doctors, pharmacists, and well-meaning family members have told older adults take calcium and vitamin D to keep bones strong and stay on their feet. It became one of the most widely repeated pieces of health advice in modern medicine. But a large updated review of nearly 70 clinical trials and more than 153,000 people has arrived at a conclusion that may surprise millions of supplement users.
Calcium, vitamin D, or the two taken together appear to offer little to no protection against broken bones or falls for many generally healthy, community-dwelling older adults.
Falls are not a minor inconvenience for older people. Almost a third of adults aged 65 and older experience at least one fall every year. Falls are the leading cause of both fatal and non-fatal injuries in that age group, and as much as 85% of older adults who have experienced a fall develop a fear of falling again, which can reduce their activity and make future falls more likely. Half of women and one in five men will suffer a low-trauma fracture during their lifetime. Against that backdrop, the widespread recommendation of these supplements made intuitive sense. The science, however, tells a different story.
Researchers led by Olivier Massé and colleagues, based at a hospital and research center in Montreal, Canada, conducted a large updated review of the available randomized trial evidence. Their findings, published in The BMJ, cut against decades of clinical habit and against costly supplement use, including one cited estimate of about $2 billion a year to provide calcium and vitamin D to adults over 50 with osteoporosis in the U.S. and European Union.
69 Trials and 153,000 People Found No Meaningful Fracture Protection
Rather than running a new experiment, the team gathered and analyzed every high-quality clinical trial available on the topic, combining results to get a clearer picture than any single study could provide. Searching multiple major medical databases and clinical trial registries through February 2025, they identified 69 qualifying trials involving 153,902 participants. Studies had to randomly assign adults to a supplement or placebo group and track fractures or falls. Participants already taking prescription drugs for bone loss were excluded.
Who Was in These Calcium and Vitamin D Trials
About 87% of participants lived independently in the community, and 73% were not classified as high risk for fractures or falls. The median age across all trials was 71 years. That profile matches the population most likely to be buying these supplements at the pharmacy, a population taking calcium and vitamin D as a general preventive measure.
Evidence for people at genuinely high risk, including those in residential care, with a history of fractures, or with severely low vitamin D levels, was considerably thinner. The researchers flagged that gap explicitly.
Vitamin D Alone Showed No Benefit for Fractures or Falls
For vitamin D taken alone, the results were flat. Across 36 trials involving more than 92,000 participants, fracture risk was essentially identical between people who took vitamin D and those who did not. Researchers rated the certainty of this finding as high under the GRADE system, a standard method for judging confidence in medical evidence. The same held true for hip fractures, spine fractures, arm and leg fractures, and falls.
Calcium alone, across 11 trials with about 9,000 participants, similarly showed little to no effect. One unusual finding: the data showed a trend toward more hip fractures in people taking calcium, though the researchers called this result “biologically implausible” and cautioned against reading it as evidence that calcium causes hip fractures.
Combined calcium and vitamin D did produce numbers that cleared the bar for statistical significance on some outcomes, but the reductions were too small to matter clinically. When the researchers stress-tested the findings by recalculating results in different ways, that conclusion held.
A Question of Cost, Habit, and Side Effects
Calcium supplements are frequently hard to swallow and poorly tolerated, often causing constipation and bloating. One large trial previously linked combined calcium and vitamin D supplementation to a modestly higher rate of kidney stones. Some data have suggested a possible connection between calcium supplements and heart attack risk, though the research on that point remains conflicting.
Importantly, the findings do not apply to people already taking prescription osteoporosis medications, and that recommendation remains intact. People prescribed calcium or vitamin D for severe deficiency, specific bone disorders, or other medical reasons should consult a clinician before changing anything.
For the millions of otherwise healthy older adults taking these supplements largely on the assumption that more bone-related nutrients must mean stronger bones, the largest synthesis of available randomized trial evidence has not backed that assumption up. Future research may yet clarify whether certain vulnerable populations stand to benefit. For now, the science points toward exercise, fall prevention, and home safety modifications as the more reliable tools for keeping older adults on their feet.
Disclaimer: This article is not meant to offer medical advice. Always speak with a qualified healthcare professional before making changes to your medications, supplements, or health routine.
Paper Notes
Limitations
The researchers identified several important limitations. A number of subgroup analyses included only a small number of trials and participants, making those findings harder to interpret with confidence. The team also did not conduct within-trial subgroup analyses, considered the most rigorous method for comparing outcomes across patient groups. Thresholds used to define a “clinically meaningful” improvement were established by the authors through consensus, not formal patient input, meaning other researchers might draw those lines differently.
An important concern involves the control groups: many studies either allowed participants to take their own calcium or vitamin D supplements outside the trial, or did not clearly prohibit it. If people in the placebo groups were quietly supplementing on their own, the true difference between groups could be smaller than detected, potentially masking a real benefit. Short follow-up periods and small sample sizes in many included trials also limit the ability to detect modest long-term effects. The findings cannot be applied to people taking prescription osteoporosis drugs.
Funding and Disclosures
No external funding was received for this review. Article processing charges were covered by CIUSSS du Nord-de-l’Île-de-Montréal. Some authors received payments in the past 36 months from non-industry organizations for education activities related to osteoporosis, fracture prevention, or calcium and vitamin D; the authors stated those organizations do not have interests affected by the manuscript’s content. Most trials included in the review reported non-industry funding, though drugs or supplements were supplied by industry in many cases. No patients or members of the public were formally involved in the design or conduct of this review.
Publication Details
Paper Title: Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis | Authors: Olivier Massé, Claudia Mei Mercurio, Sébastien Dupuis, Maya Al Sahwi, Alexandra Arruda, Gabriel Dallaire, Katherine Desforges, Nicolas Dugré, David Williamson | Author Affiliations: Department of Pharmacy, CIUSSS du Nord-de-l’Île-de-Montréal, Québec, Canada; Research Center, CIUSSS du Nord-de-l’Île-de-Montréal, Québec, Canada; Department of Pharmacy, McGill University Health Centre, Québec, Canada; Faculty of Pharmacy, University of Montreal, Québec, Canada | Journal: The BMJ | Citation: BMJ 2026;393:e088050 | DOI: 10.1136/bmj-2025-088050 | Systematic Review Registration: PROSPERO CRD42023483915







